Last updated: August 21, 2026
Saxagliptin and metformin hydrochloride is a mature fixed-dose combination marketed in the United States as Kombiglyze XR by AstraZeneca. The product combines the DPP-4 inhibitor saxagliptin with extended-release metformin for adults with type 2 diabetes. Its commercial trajectory has been shaped by declining DPP-4 growth, generic metformin availability, safety concerns associated with saxagliptin, and competition from SGLT2 inhibitors and GLP-1 receptor agonists.
AstraZeneca does not report Kombiglyze XR revenue as a consistently separate global line item. Public financial disclosures generally group it with Onglyza, other diabetes products, or broader cardiovascular, renal, and metabolic portfolios. The product therefore has strategic relevance but limited standalone visibility in company financial statements.
What is saxagliptin and metformin hydrochloride?
Saxagliptin and metformin hydrochloride is an oral, twice-daily or once-daily fixed-dose combination depending on formulation and market. Kombiglyze XR uses extended-release metformin and is administered once daily with the evening meal.
| Attribute |
Product information |
| Active ingredients |
Saxagliptin and metformin hydrochloride |
| Drug class |
DPP-4 inhibitor plus biguanide |
| Primary indication |
Type 2 diabetes mellitus |
| U.S. brand |
Kombiglyze XR |
| U.S. sponsor |
AstraZeneca |
| FDA approval |
2010 |
| Dosage form |
Extended-release oral tablets |
| Main mechanism |
Increased incretin activity plus reduced hepatic glucose production |
| Key competitors |
Janumet, Janumet XR, Galvus Met in some markets, generic metformin combinations, SGLT2 and GLP-1 therapies |
| Major commercial limitation |
Older treatment class with weaker growth than newer cardiometabolic therapies |
Saxagliptin inhibits DPP-4, increasing endogenous GLP-1 and GIP activity. Metformin reduces hepatic glucose production and improves insulin sensitivity. The combination is used when metformin alone does not provide adequate glycemic control or when patients are already receiving both components.
The product does not contain insulin and is not approved for type 1 diabetes or diabetic ketoacidosis. The FDA label includes renal dosing restrictions and contraindications associated with metformin, including severe renal impairment and metabolic acidosis risk (U.S. Food and Drug Administration [FDA], 2023).
How large is the market for saxagliptin and metformin?
The underlying type 2 diabetes market is large, but the addressable market for this specific combination is mature and declining in developed countries.
The International Diabetes Federation estimated that 537 million adults aged 20 to 79 were living with diabetes globally in 2021, with the total projected to reach 643 million by 2030 and 783 million by 2045 (International Diabetes Federation, 2021). That structural growth supports demand for oral diabetes treatments. It does not translate directly into growth for saxagliptin and metformin because treatment guidelines and prescribing patterns have shifted toward medicines with cardiovascular, renal, and weight-loss benefits.
Market drivers
Key demand drivers include:
- Rising prevalence of type 2 diabetes.
- Continued use of low-cost oral combinations in emerging markets.
- Patient and physician familiarity with metformin.
- Convenience of combining two agents in one tablet.
- Use in patients who require glucose lowering without hypoglycemia associated with insulin or sulfonylureas.
Market restraints
The commercial restraints are stronger in the United States and Western Europe:
- Metformin is widely available as a low-cost generic.
- DPP-4 inhibitors have limited effect on weight and do not generally deliver the cardiovascular or renal outcome advantages associated with SGLT2 inhibitors and GLP-1 receptor agonists.
- Saxagliptin carries a heart-failure hospitalization warning based on the SAVOR-TIMI 53 cardiovascular outcomes trial.
- Multiple branded DPP-4 combinations compete for the same patients.
- Payers increasingly use step therapy and prefer generic metformin or lower-cost diabetes regimens.
- Newer diabetes products command greater physician attention and commercial investment.
The product remains more defensible in markets where fixed-dose combinations are preferred and access to newer injectable or cardiometabolic therapies is limited.
How has the financial trajectory changed?
Kombiglyze XR’s financial trajectory has followed the broader decline of saxagliptin-based products rather than the growth of the diabetes market as a whole.
AstraZeneca’s public reporting has historically grouped Onglyza and Kombiglyze revenue, preventing a reliable standalone revenue series for Kombiglyze XR. The disclosed pattern has been a decline from the product family’s earlier peak as patent exposure increased, DPP-4 competition intensified, and treatment shifted toward newer classes.
| Financial factor |
Effect on Kombiglyze XR |
| Large diabetes population |
Supports baseline demand |
| Generic metformin |
Reduces combination pricing power |
| DPP-4 class maturity |
Limits prescription growth |
| SGLT2 and GLP-1 adoption |
Diverts new-patient starts |
| Saxagliptin heart-failure warning |
Creates prescribing friction |
| Patent expiry and generic entry |
Exerts direct price pressure |
| Emerging-market demand |
Extends product life cycle at lower prices |
| AstraZeneca portfolio strategy |
Reduces emphasis on legacy DPP-4 products |
The product’s revenue profile is therefore likely characterized by declining branded sales, lower average selling prices, and residual demand in established patients. The largest financial risk is not an abrupt loss of all demand. It is progressive erosion of price, formulary position, and new-patient initiation.
AstraZeneca’s diabetes strategy has increasingly centered on newer growth platforms, including Farxiga, rather than relying on saxagliptin combinations. Farxiga’s use in chronic kidney disease, heart failure, and type 2 diabetes gives it a broader commercial profile than Kombiglyze XR. That portfolio shift reduces the likelihood that AstraZeneca will make major new investment in saxagliptin-based expansion.
What FDA regulatory issues affect saxagliptin and metformin?
The FDA approved saxagliptin as Onglyza in 2009 and approved Kombiglyze XR in 2010. The product remains an approved prescription treatment for type 2 diabetes, subject to labeling restrictions and renal-dose adjustments.
The most important regulatory issue is the cardiovascular safety finding from SAVOR-TIMI 53. The trial found that saxagliptin met the noninferiority requirement for major adverse cardiovascular events but increased hospitalization for heart failure. Heart-failure hospitalization occurred in 3.5% of patients receiving saxagliptin versus 2.8% receiving placebo, with a hazard ratio of 1.27 (Scirica et al., 2013).
The FDA subsequently added heart-failure warnings to the labels for saxagliptin-containing products. Patients with a history of heart failure or renal impairment receive particular attention in prescribing decisions. This warning does not remove the product from the market, but it narrows its attractiveness relative to diabetes treatments with demonstrated heart-failure or renal benefits.
The metformin component creates a separate regulatory constraint. Renal function must be assessed before and during treatment, and metformin is contraindicated in severe renal impairment. The combination also has dosage limitations because saxagliptin dosing is reduced in patients with moderate or severe renal impairment.
What patents protect saxagliptin and metformin hydrochloride?
Protection for the combination has historically involved several categories:
- Saxagliptin compound patents.
- Salt and crystalline-form patents.
- Fixed-dose combination patents covering saxagliptin with metformin.
- Extended-release formulation patents.
- Manufacturing and pharmaceutical-composition claims.
- Method-of-use claims for treating type 2 diabetes.
The commercially relevant protection is not determined solely by the original saxagliptin compound patent. A generic manufacturer seeking to market the combination must assess the remaining patent claims covering the specific dosage form, strength, formulation, and use.
Patent protection by claim type
| Patent category |
Commercial relevance |
| Saxagliptin compound |
Protects the active DPP-4 inhibitor, but may expire before later formulation claims |
| Combination composition |
Can delay generic versions containing both saxagliptin and metformin |
| Extended-release formulation |
Particularly relevant to Kombiglyze XR |
| Dosage-strength claims |
May create different timing for individual strengths |
| Method-of-use claims |
Can affect labeling and skinny-label launch strategies |
| Manufacturing claims |
May raise technical barriers but usually do not block all generic routes |
The earliest saxagliptin protection has expired or reached the end of its term in several jurisdictions. Later combination and formulation protection has been more commercially important for Kombiglyze XR. U.S. patent status must be evaluated against the current FDA Orange Book listings, patent-term adjustments, pediatric extensions, litigation outcomes, and any applicable settlement provisions (FDA, n.d.-a).
When does saxagliptin and metformin lose exclusivity?
The product’s exclusivity loss occurs in stages rather than on one universal date.
United States
Kombiglyze XR received FDA approval in 2010. Its five-year new chemical entity exclusivity did not extend to the full fixed-dose combination in the same manner as a newly approved active ingredient because saxagliptin had already been approved separately. The commercially significant barriers have instead involved listed patents and formulation or combination claims.
Saxagliptin’s earliest core patent protection has generally expired. Later U.S. patents covering the combination and extended-release product have had expiration dates extending into the 2020s. The precise generic-entry date depends on:
- The Orange Book patent listing in effect for each strength.
- Whether an ANDA applicant filed a Paragraph IV certification.
- Patent litigation and any 30-month stay.
- Settlement terms between AstraZeneca and an ANDA applicant.
- Pediatric exclusivity or patent-term adjustment.
- Whether the generic launches at risk.
A blanket statement that all U.S. protection ended on the compound-patent expiration date would therefore be inaccurate.
Europe and other markets
European protection varies by country and by the existence of national validation, supplementary protection certificates, and local litigation. The product has faced earlier erosion in some markets than in the United States. In lower-priced markets, generic metformin combinations and local DPP-4 competitors can reduce commercial value even before all patent claims expire.
What is the Orange Book status of Kombiglyze XR?
Kombiglyze XR is an FDA-approved prescription drug listed in the FDA Orange Book framework. The Orange Book identifies approved drug products, therapeutic-equivalence information, and listed patents and exclusivity information where applicable.
For this product, Orange Book analysis should distinguish:
- The reference listed drug for the extended-release combination.
- Individual strengths and dosage forms.
- Whether an approved ANDA has a therapeutic-equivalence code.
- Listed patents that remain active for the specific product.
- Patent certifications submitted by ANDA applicants.
- Any exclusivity that applies to an individual supplement rather than the original approval.
The presence of an Orange Book-listed patent does not automatically prevent generic approval. A Paragraph IV certification can trigger patent litigation. Conversely, patent expiry does not guarantee immediate commercial entry if the generic lacks FDA approval, manufacturing capacity, or favorable economics.
Which companies are challenging saxagliptin and metformin exclusivity?
Generic-drug companies have targeted saxagliptin products and saxagliptin/metformin combinations through ANDA filings and patent certifications. The relevant competitive set includes large generic manufacturers such as Teva, Mylan, Lupin, Dr. Reddy’s Laboratories, Sun Pharmaceutical, and other regional suppliers, although the status of individual filings changes over time.
Paragraph IV risk
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the patent owner files suit within the statutory period, FDA approval can be stayed for up to 30 months, subject to court decisions and regulatory exceptions.
The highest-value challenge targets are usually:
- The extended-release combination.
- High-volume strengths.
- Formulation patents with later expiry dates.
- Patents that cover the commercial product rather than the underlying active ingredient alone.
A generic company may also pursue a section viii statement that omits a patented method of use from its label. That strategy is less useful where the remaining claims cover the composition or formulation itself.
What litigation and settlement agreements affect the product?
Saxagliptin and Kombiglyze XR have been exposed to the standard litigation pattern for branded oral medicines: ANDA filings, Paragraph IV notices, patent-infringement suits, and potential settlement arrangements.
Publicly reported settlement terms in pharmaceutical patent cases can include:
- A licensed future generic-entry date.
- A nonexclusive license.
- Restrictions on launch timing or product formulation.
- Agreements covering both Onglyza and Kombiglyze XR.
- No-admission provisions.
- Commercial terms that are not publicly disclosed.
The financial effect of settlement is often larger than the nominal patent expiration date. A settlement can convert uncertain litigation risk into a defined launch date, allowing AstraZeneca to plan inventory and pricing while allowing a generic company to prepare manufacturing and distribution.
No single litigation event determines worldwide entry. U.S. proceedings affect the largest branded market, while European and other national cases follow separate legal calendars.
How strong is the patent estate for saxagliptin and metformin?
The patent estate is moderate for the combination but weak as a long-term growth asset.
Strengths
- Multiple patent categories can create layered protection.
- Extended-release formulation claims may be harder to design around than simple immediate-release composition claims.
- Metformin provides a familiar and commercially durable backbone.
- The combination may retain value in markets with limited access to newer diabetes agents.
Weaknesses
- Saxagliptin is an established small molecule with an aging core patent estate.
- Generic metformin puts pressure on the branded combination’s price.
- DPP-4 inhibitors have limited differentiation within the broader diabetes market.
- Formulation patents can be challenged through alternative excipients, release profiles, or manufacturing processes.
- The heart-failure warning weakens clinical positioning.
- Newer therapies have stronger outcome-based marketing claims.
The estate is more effective at delaying direct substitution than at supporting premium pricing. Once a therapeutically equivalent generic is available, the combination is likely to experience substantial erosion.
What generic launch scenarios exist?
Scenario 1: Delayed entry after patent settlement
A settlement-defined launch date would produce a sharp but managed decline. AstraZeneca could preserve branded pricing until launch, after which pharmacy benefit managers would likely favor the generic.
Scenario 2: At-risk launch
An ANDA applicant could launch before final resolution if it believes the relevant patents are invalid or not infringed. This would expose the manufacturer to damages and an injunction but could accelerate price erosion.
Scenario 3: Formulation-specific entry
A generic may enter for selected strengths or formulations while other strengths remain protected. This can create partial erosion rather than a single market-wide event.
Scenario 4: Regional generic erosion
In markets without effective patent barriers, local manufacturers may reduce price and share before U.S. entry. This is especially relevant where fixed-dose DPP-4/metformin combinations are common.
Scenario 5: Limited commercial entry
A generic may receive approval but launch only selectively if expected net price, manufacturing complexity, or market size is unattractive. Extended-release products can have lower expected returns than standard immediate-release generics.
How does Kombiglyze XR compare with competing diabetes combinations?
| Product or class |
Principal advantage |
Principal weakness relative to Kombiglyze XR |
| Janumet or Janumet XR |
Strong sitagliptin brand recognition and broad clinical use |
Same DPP-4 class limitations; exposed to generic competition |
| Generic metformin |
Low cost and guideline familiarity |
Lacks saxagliptin’s additional glucose-lowering effect |
| SGLT2 inhibitors |
Heart-failure and renal outcome benefits for several agents |
Higher cost, contraindications, and genitourinary adverse effects |
| GLP-1 receptor agonists |
Greater glucose lowering and weight loss |
Injectable or specialized delivery, cost, and supply constraints |
| Sulfonylureas |
Low acquisition cost and rapid glucose lowering |
Hypoglycemia and weight gain |
| Basal insulin |
Strong glucose-lowering capacity |
Injection burden and hypoglycemia risk |
Kombiglyze XR can remain useful for patients who need oral therapy and do not require weight loss or cardiorenal risk reduction. It is less competitive for newly diagnosed patients with obesity, heart failure, chronic kidney disease, or established cardiovascular disease.
What revenue exposure does AstraZeneca face?
AstraZeneca’s direct exposure is limited by the product’s declining scale and by the company’s broader portfolio. The larger strategic risk is substitution within the diabetes franchise rather than a major enterprise-wide revenue shock.
The principal exposure points are:
- Loss of branded DPP-4 revenue after generic entry.
- Lower reimbursement and formulary access.
- Reduced cross-selling of Onglyza and Kombiglyze XR.
- Inventory write-downs near generic launch.
- Legal and manufacturing costs associated with patent defense.
- Potential cannibalization by newer AstraZeneca products.
The company’s financial sensitivity is greatest in countries where the product remains branded, reimbursed, and prescribed at meaningful volume. In the United States, generic entry would likely create the sharpest price decline. In emerging markets, volume may persist longer, but at materially lower prices.
What manufacturing and intellectual-property barriers remain?
Kombiglyze XR does not have the manufacturing complexity of a biologic, injectable peptide, or sterile product. The principal technical issues involve:
- Consistent extended-release performance.
- Uniform distribution of saxagliptin and metformin.
- Stability of the finished tablet.
- Control of dissolution profiles.
- Bioequivalence across strengths.
- Scale-up and batch reproducibility.
- Demonstration that the formulation does not infringe active claims.
These barriers can delay or reduce the number of generic entrants, but they are unlikely to create a durable barrier comparable to a complex biologic manufacturing process. The product is a small-molecule oral tablet, so long-term generic substitution remains the central commercial risk.
Key Takeaways
- Saxagliptin and metformin hydrochloride is a mature oral type 2 diabetes combination marketed in the United States as Kombiglyze XR.
- AstraZeneca does not provide a consistently separate revenue line for Kombiglyze XR, limiting precise standalone financial analysis.
- The product family’s financial trajectory has declined as DPP-4 inhibitors lost momentum and SGLT2 and GLP-1 therapies gained preference.
- Saxagliptin’s heart-failure hospitalization signal remains a material prescribing and positioning disadvantage.
- U.S. exclusivity depends on later combination and extended-release patents, not only on the original saxagliptin compound patent.
- Paragraph IV filings and settlement agreements can determine generic entry timing before or after nominal patent expiry.
- The patent estate is moderate for delaying direct generic substitution but weak as a platform for long-term premium pricing.
- The greatest financial risk is rapid price erosion after FDA-approved generic entry, especially in the United States.
- The product is more likely to persist through lower-priced emerging-market sales and established-patient use than through renewed branded growth.
FAQs
Is saxagliptin and metformin hydrochloride still FDA approved?
Yes. Kombiglyze XR remains an FDA-approved treatment for adults with type 2 diabetes, subject to renal, metformin, and heart-failure-related labeling restrictions.
Does saxagliptin cause heart failure?
Saxagliptin was associated with a higher rate of hospitalization for heart failure in SAVOR-TIMI 53. The FDA label includes a warning and recommends consideration of treatment alternatives in certain high-risk patients.
Is there a generic version of Kombiglyze XR?
Generic availability depends on the jurisdiction, formulation, strength, FDA approval status, and remaining listed patents. Approval and commercial launch are separate events.
Can a patient substitute generic metformin for Kombiglyze XR?
Generic metformin does not provide saxagliptin. Substitution may require a separate prescription for saxagliptin or another glucose-lowering agent and must account for formulation, dose, renal function, and payer requirements.
Which newer medicines are most likely to replace Kombiglyze XR?
SGLT2 inhibitors and GLP-1 receptor agonists are the principal replacement classes when cardiovascular, renal, weight-loss, or stronger glucose-lowering benefits are priorities. Generic metformin remains the main low-cost alternative.
References
AstraZeneca PLC. (2023). Annual report and Form 20-F 2023. AstraZeneca.
International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). International Diabetes Federation.
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ianchulev, T., Solomon, S. D., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine, 369(14), 1317-1326. https://doi.org/10.1056/NEJMoa1307684
U.S. Food and Drug Administration. (2023). Kombiglyze XR prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
